Cushing’s Disease Treatment Breakthrough for Dogs

Natural Treatment for Cushings Disease in Dogs

“My 12 year old dachshund was recently diagnosed with Cushing’s disease. My Vet recommended that I look the Cushing’s Killer Combo. It’s 5 weeks now and we can already see an improvement, without any side effects. She’s drinking less, urinating less and panting less” Janet Santee – La Habra, CA

Brad Solomon, founder of Pranapets.com, an Herbal Remedy Manufacturer specializing in CBD Oil for dogs and cats, was constantly hearing from customers who had dogs with health issues related to Cushing’s disease.

Over 100,000 middle age to senior dogs are diagnosed with Cushing’s disease every year.

Cushing’s disease in dogs develops when their own body overproduces cortisol. Hyperadrenocorticism in dogs generally affects middle-aged to older animals.

Symptoms of Cushing’s disease include increased thirst and urination, loss of hair, panting, pot bellies, obesity, and a general lack of interest in things that dogs normally like to do.

Solomon stated that “Cushing’s disease in dog’s can have similar characteristics to Alzheimer’s disease in people and aside from the physical issues it presents it can change a dog’s personality. Dogs become forgetful, disinterested and can even become aggressive which is very depressing for pet parents. Prescription drug options like Trilostane, Mitotane and Anipryl can be effective but the many side-effects can sometimes outweigh the benefits. We wanted to develop a natural remedy for Cushing’s disease in dogs.”

Solomon, his veterinarian and his product formulator took over a year to formulate and test his Adrenal Support Remedy to address symptoms of Cushing’s disease, which is now one of his most popular selling items.

“One day I had an epiphany when my next door neighbor Sue told me a story about her Maltese, Cheri. Sue had been ordering Prana Pets Adrenal Support, C Support and CBD Oil for Cheri’s Cushing’s disease and Arthritis. Sue remarked that somehow Cheri’s internal clock had turned back. Cheri was peeing and panting less, not staring into space anymore and was acting like her younger pain-free self. Sue’s experience with Cheri gave me that spine tingling, joyous moment and the Cushing’s Killer Combo was born.”

Solomon’s #1 selling system for the past 2 years is the Cushing’s Killer Combo which contains, High Spectrum CBD Oil, C-Support for immunity and Adrenal Support to help address the symptoms related to Cushing’s disease. Solomon also noted that it’s safe to use with most prescription meds. Many of the customers are able to eliminate the prescription medications altogether after consulting with their vet.

In January 2019, Solomon surveyed 150 customers who purchased the Cushing’s Killer Combo system and administered it to their dog for a minimum of 90 days.

Some of the survey highlights include;

  • 8/10 of those surveyed for excessive drinking and urination believed that Prana Pets Cushing’s Killer Combo was effective in reducing the amount of water consumed and the frequency of urination
  • 8.2/10 of those surveyed for hair loss believed that Prana Pets Cushing’s Killer Combo was effective in reducing their dog’s hair loss
  • 8/10 of those surveyed for believed that Prana Pets Cushing’s Killer Combo Oil was effective in reducing their dog’s anxiety or stress
  • 8.7/10 of those surveyed for having a ravenous appetite believed that Prana Pets Cushing’s Killer Combo was effective in reducing their hunger within 2 weeks

To see the full survey results go to: https://www.pranapets.com/pages/cushings-survey.

About Prana Pets

Based in Delray Beach, FL, Prana Pets started in 2016. Prana Pets believes that nature has provided us with everything necessary to sustain deep, lasting health in ourselves as well as our pets.

For this reason, every Prana Pets formula utilizes all-natural compounds of premium quality and potency to ensure that your pets attain the lasting, vibrant health they deserve. Every bottle leaving their facility is formulated to satisfy the rigorous demands of evidence-based research while incorporating the wisdom of healing traditions across the world.

The Prana Pets team of experts in the field of nutrition, herbalism and homeopathy are actively involved in promoting a holistic view of health, not just as a philosophy but as a lifestyle. The company strongly believes and understands that a holistic approach to health can produce radical, lasting health improvements that synthetic drugs alone cannot achieve. Learn more at: https://www.pranapets.com/.

As Microsoft Reports Earnings, My Focus Is on Cloud Computing

Bring It

An oldie, but a good-ie. can it be? Steady Eddie. Somehow, my twenties turned into my fifties. Somehow, being shocked that Dwight Gooden was younger than I, yet the toast of the National League… turned into being shocked when I can read anything at all without fumbling for my glasses. Through most of my career, since going public in 1986, (another Gooden reference?)… there has been Microsoft (MSFT) . Windows. Office. Still useful, but the story goes on. Way beyond.

Tonight’s The Night

Microsoft will report the firm’s fiscal third quarter this evening once those twin bells at 11 Wall Street and Times Square stop ringing. The street looks for EPS of one dollar flat on revenue of $29.84 billion. If realized, this will be a year over year increase of 11.3%, growth well above broader expectations for the SP 500.

For me, a trader long this name, the focus has to be on cloud computing, as it now has to be for the software industry altogether. Yes, recurring revenue products like those already mentioned are valuable drivers of performance. Yes, many are betting on gaming, but gaming has been balky this year. A stronger February has been followed by a weak again March decline in sales across that industry. That said, Azure is how success will be measured for Microsoft. Azure will determine the path that the stock price will take moving forward. So let’s focus on that.

Cloudy Days

Last week, KeyBanc analyst Brent Bracelin indicated that he sees subscription based APR for Azure topping the $12 billion mark, while he sees subscription APR for Office 365 beating $20 billion. By the same token, UBS analyst Jennifer Swanson Lowe, according to Barron’s sees 2019 revenue for Microsoft, along with Abobe (ADBE) , and Salesforce (CRM) topping broader industry-wide expectations. Then, also last week, Keith Weiss of Morgan Stanley named Microsoft as representing the “best risk/reward in software.” So… the analyst community is convinced. Are we? That’s more important. Analysts are fine, but unlike them, when we are wrong, we actually lose money.

I am watching closely two items regarding Microsoft’s cloud business. One is just how fast Azure’s hybrid cloud for business is growing. How attractive are businesses finding this offering versus the chief competitor, which is Amazon’s (AMZN) AWS service. That brings us to the pentagon’s JEDI program. Last week, Microsoft revealed two data centers that have been designed and created solely for classified information. Remember that Amazon has already been cleared to host top secret data for both the CIA and the DOD, while Microsoft still awaits such clearance. The DOD’s JEDI program which is what the military’s cloud contract is known as, is worth $10 billion, and has devolved into a winner takes all sort of playoffs. The last two competitors standing are Amazon and Microsoft, after IBM (IBM) , and Oracle (ORCL) were eliminated and Alphabet (GOOGL) voluntarily dropped out. We will need to hear comment on this.

The Chart

There is obviously a lot to like here. Whether one trusts the blue Pitchfork, or the orange Cup with Handle, both have been supportive throughout 2019, the breakout out of that handle probably more so of late. As you can easily see Money Flow has been robust, while the daily MACD and Relative Strength nearly too robust. Perhaps overbought.

Like I have said, I like Microsoft. That said, we are sort of closing in on my target price of $132. I would not be surprised to see a knee-jerk in either direction after the call tonight. That said, the cloud is the future (along with 5G), and Microsoft is a dominant force in providing that cloud across U.S. business. I would think that these shares continue to move higher, even if there is a spate of profit taking this evening.

Microsoft 

Target Price: $132

Add: $112

Panic: $103

Note 1: I have enough exposure, but a trader interested, but not willing to pay current prices could target next earnings season by…..

– Selling one MSFT  $115 July put (value: $1.73)

– Selling one MSFT $110 July put (value: $1.02)

Net debit: $2.75

Note 2: The trade here will have pocketed $275 upfront. In exchange, the trader has accepted the risk of having to buy 100 shares of MSFT at $115, and maybe another 100 shares of MSFT at $110 in July. Worst case… the trader ends up long 200 shares of MSFT at a net basis of $111.13, with the shares trading below $110. The point being that the net basis is below where I see the name as an add.

(Microsoft, Salesforce, Amazon and Alphabet are holdings in Jim Cramer’s Action Alerts PLUS member club. Want to be alerted before Jim Cramer buys or sells MSFT, CRM, AMZN or GOOGL? Learn more now.)

Technologies to Improve Patient Adherence and Trends in Pharmaceutical Manufacturing to be Discussed by Catalent at CPhI North America

Catalent (booth 1206), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that its experts will participate in two conference sessions at the upcoming CPhI North America tradeshow at the Lakeside Center at McCormick Place, Chicago, on April 30 – May 2, 2019.

On Tuesday, April 30 at 9:45 a.m., Ronak Savla, Pharm.D., Ph.D., Scientific Affairs Manager, and co-chair of the Catalent Applied Drug Delivery Institute, has been invited to join the “Building a Better Drug: Strategies to Enhance Patient Drug Regimen” panel session. He will discuss roadblocks to patient adherence, and technologies and processes that can be employed to mitigate these problems including formulation methods, new dosage forms, excipients, and alternative delivery technologies.

On Wednesday, May 1 at 1:30 p.m., Mike Valazza, Vice President, Business Development, Oral Drug Delivery North America, will present “Advancements in Manufacturing Solutions”. His presentation will discuss current trends in pharmaceutical manufacturing, including the increase in the number of expedited programs, the need for integrated end-to-end solutions from Phase 1 to commercialization, and the adoption of technologies to assist in getting products to market faster.

Dr. Savla is responsible for the strategy of the scientific communications plan, management of external collaborations, scientific assessment of novel drug delivery technologies, oversight of internal technology development, and leadership of Catalent’s Scientific Excellence Initiative. He leads several initiatives within the company focusing on patient-focused drug design, including a collaboration with Rutgers University School of Pharmacy to investigate the challenges in pediatric dose form design. He received both his Doctor of Pharmacy degree and his doctorate from Rutgers University, New Brunswick, New Jersey.

Mr. Valazza has over 20 years’ experience in the pharmaceutical industry. Prior to joining Catalent in 2001, he held senior positions at several companies including International Processing Corporation, Glatt Air Techniques and Schering Pharmaceuticals. Mr. Valazza is a registered pharmacist, and a member of a variety of professional organizations including the American Pharmaceutical Association, the American Association of Pharmaceutical Scientists, and the Controlled Release Society. He received a bachelor’s degree in pharmacy from Rutgers University, New Brunswick, New Jersey.

At the show, Catalent executives will be available to discuss the recently announced acquisition of Paragon Bioservices, Inc., a leading viral vector development and manufacturing partner for gene therapies, and will also share news of further network expansions. Catalent will be exhibiting and showcasing its multiple innovative technologies, and will host a bourbon tasting networking reception at Drumbar on Wednesday, May 1 at 7:30 p.m. For more information visit the Catalent booth 1206, or visit catalent.com.

To arrange a meeting with any of the attending Catalent executives at the event, contact Ed Dutton at NEPR – edward(at)nepr.agency.

About Catalent

Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With more than 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs over 11,000 people, including over 1,800 scientists, at more than 30 facilities across five continents, and in fiscal year 2018 generated approximately $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit http://www.catalent.com.

More products. Better treatments. Reliably supplied.™